[Recent therapeutic strategy for thrombotic thrombocytopenic purpura].
Yoshihiro
Y
Fujimura
Masanori
M
Matsumoto
Ayami
A
Isonishi
Hideo
H
Yagi
Koichi
K
Kokame
Toshiyuki
T
Miyata
D051722:ADAM Proteins / Q000008:administration & dosage / Q000032:analysis / Q000172:deficiency / Q000502:physiology; D000071120:ADAMTS13 Protein; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D001696:Biomechanical Phenomena; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage; D010949:Plasma; D010951:Plasma Exchange; D010974:Platelet Aggregation; D055503:Protein Multimerization; D020551:Pulse Therapy, Drug; D011697:Purpura, Thrombotic Thrombocytopenic / Q000097:blood / Q000151:congenital / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D000069283:Rituximab; D013314:Stress, Mechanical; D014841:von Willebrand Factor / Q000378:metabolism
D058846:Antibodies, Monoclonal, Murine-Derived; D011994:Recombinant Proteins; D014841:von Willebrand Factor; D000069283:Rituximab; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human; D008775:Methylprednisolone